Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?
View More
(CME Credit) Addressing Healthcare Inequities Diabetic Retinal Vascular Disease: How Can We Address Ethnic Disparities within the Clinic?
View More
(COPE Credit) Addressing Healthcare Inequities Diabetic Retinal Vascular Disease: How Can We Address Ethnic Disparities within the Clinic?
View More
Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies
View More
(CME Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME/CNE Credit) Community Practice Connections™: Restoring the Surface Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
Aligning Clinical Trial Retreatment Criteria to Clinical Practice
March 15th 2024Judy Kim, MD and Peter Kaiser, MD reflect on the varying criteria for shortening or extending treatment intervals in clinical trials, emphasizing the need for standardization in large-scale studies. They highlight the importance of adapting trial criteria to clinical practice.
Overview of the Newest Therapies for AMD and DME: Faricimab and Aflibercept 8mg
March 15th 2024Experts discuss the efficacy and durability of newer therapies, focusing on faricimab and the high dose of aflibercept, highlighting the promising clinical trial results, maintaining comparable visual acuity efficacy while achieving longer durability.
Afredo A. Sadun, MD, PhD, discusses research targeting LHON
Scientists at the Doheny Eye Institute, in collaboration with UCLA chemists, demonstrate how a single gene mutation in an enzyme complex known to produce the energy required by cells causes a sudden, blinding disease.